Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key ...
The biotechnology sector has not seen a sustained rally in 2024 despite initial optimism and ongoing progress. Sarepta Therapeutics’ Elevidys, a $3.2 million gene therapy for Duchenne muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results